Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consens

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report […]

Related Keywords

Arcutis Biotherapeutics , Connor Clark Lunn Investment Management Ltd , Needham Company , Arcutis Biotherapeutics Inc , Hennion Walsh Asset Management Inc , Alphacentric Advisors , Nasdaq , Prelude Capital Management , Arcutis Biotherapeutics Company Profile , Cantor Fitzgerald , Wadegw Inc , Get Free Report , Lunn Investment Management , Centric Advisors , Capital Management , Walsh Asset Management , Get Free , Nasdaq Arqt , Arqt , Medical , Ratings , Consensus ,